Small-cap pre-discovery opportunities — Goldman framework, April 2026

Goldman Framework: Pre-Discovery Small Caps Before Coverage Catches Up

The highest-velocity gains in small caps usually happen in two phases: first when fundamentals inflect, and second when institutional coverage scales. Most investors focus on phase two because it feels safer. This report is designed for phase one, where asymmetry is largest but selectivity must be much higher.

Our April 2026 screen targeted U.S.-listed and ADR small-cap names between roughly $100 million and $2 billion in market value, then filtered for four conditions:

1. Revenue growth at or above 25%.
2. Limited Wall Street coverage (typically 1–5 analysts).
3. Insider/founder alignment with meaningful ownership.
4. Structural tailwinds that can persist through multiple cycles.

The result is a five-name basket: INOD, NYAX, RCAT, DUOT, and COCO. Not all are equal risk. Portfolio construction matters more than story quality.

Screening Methodology and Weighting Logic

We score each name across Growth durability, Unit economics quality, Balance sheet resilience, Catalytic visibility, and Sentiment dislocation. We deliberately avoid overfitting valuation metrics because small-cap reratings are often driven by duration of growth confidence, not point-in-time multiples.

A practical weighting framework:

• Core compounders with cleaner execution receive larger initial allocations.
• Event-driven names get smaller initial sizes with room to add on confirmation.
• Defensive cash-generative names act as volatility ballast.

Name 1: Innodata (INOD) — Strong Buy

Why It Screens So Well

INOD is one of the clearest direct infrastructure beneficiaries of enterprise AI deployment. With approximately 67% year-over-year growth and still modest sell-side attention, the market has not fully internalized the durability of demand if AI data pipelines remain mission-critical.

Key Data Points

• Growth profile exceeds small-cap peer set.
• Coverage remains thin (around three analysts).
• Exposure linked to recurring enterprise workflows rather than one-off pilots.

What Could Drive Repricing

The rerating path is straightforward: maintain strong top-line growth while proving operating leverage. If management converts revenue scale into visible margin improvement over the next few quarters, valuation can transition from “speculative AI small cap” to “emerging platform infrastructure.”

Positioning

INOD is a top-two position in the basket. It has momentum but also enough fundamental depth to justify adding on execution, not just price action.

Name 2: Nayax (NYAX) — Strong Buy

Why It Is Highest Quality in the Basket

NYAX combines recurring revenue growth (about 29%), profitability progress, and substantial insider alignment (roughly 60% founder ownership). In small caps, this mix is uncommon. Many high-growth names require external capital or exhibit unstable unit economics; NYAX looks sturdier.

Key Data Points

• Founder ownership creates long-horizon incentive alignment.
• Recurring revenue base improves forecast reliability.
• Operating profile suggests quality compounder characteristics despite small-cap status.

What to Watch

The critical variable is consistency in software and transaction take-rate expansion. If recurring mix increases and margins hold, investors can justify a structurally higher multiple than traditional payments hardware peers.

Positioning

NYAX is the other top-two position. If market volatility rises, this is the name we would expect to hold fundamentals best.

Name 3: Red Cat (RCAT) — Buy

Why It Is Asymmetric

RCAT is a classic catalyst-heavy name. Reported revenue trajectory has accelerated meaningfully, and the H2 2026 SRR Tranche 3 decision is a binary but highly material event. This is not a low-risk compounder; it is an event-driven growth opportunity.

Key Data Points

• Revenue growth profile has moved into hypergrowth territory.
• Government and defense-linked demand can reprice quickly on contract wins.
• Sentiment is high-beta: strong upside if catalyst confirms, sharp drawdown if it slips.

What to Watch

Track procurement timelines, backlog conversion, and any pre-award signals around program positioning. In this setup, the sequence of information matters as much as end-state outcome.

Positioning

RCAT is sized below core names initially. We add only on concrete contract visibility. Treat as option-like exposure, not core compounder capital.

Name 4: Duos Technologies (DUOT) — Buy

Why It Is Underfollowed

DUOT fits the pre-discovery profile almost perfectly: very low analyst attention (around one analyst), strong gross margins (~61%), and a business model transition toward more recurring ARR-like economics. Markets often lag these transitions because trailing financials understate future quality.

Key Data Points

• Undercovered and therefore prone to mispricing.
• Margin structure supports SaaS-style rerating if recurring revenue scales.
• Smaller liquidity profile can amplify both upside and downside.

What to Watch

The key marker is disclosure quality around ARR and retention. If management improves reporting granularity and recurring mix climbs, institutions can underwrite longer-duration cash flows, which usually lifts valuation frameworks.

Positioning

DUOT is a mid-sized weight with add triggers tied to recurring KPI progress, not narrative headlines.

Name 5: Vita Coco (COCO) — Buy

Why It Is Included in a Growth Basket

COCO is not the fastest grower here, and that is exactly why it belongs. With founder ownership around 34%, balance sheet cleanliness, and a more established consumer brand profile, it reduces basket fragility. In a risk-off tape, this can preserve capital while higher-beta names reset.

Key Data Points

• Strong ownership alignment.
• Cleaner financial position than typical speculative small-cap peers.
• Category expansion optionality without dependency on a single binary event.

What to Watch

Monitor channel expansion efficiency, promotional intensity, and gross margin stability. If these remain healthy, COCO can fund the basket’s patience by avoiding deep drawdowns.

Positioning

COCO is the ballast allocation. We do not need heroic upside from this name; we need reliability.

Portfolio Construction: How to Build the Basket

Suggested initial weights:

• NYAX: 25%
• INOD: 25%
• DUOT: 20%
• COCO: 15%
• RCAT: 15%

This creates a barbell between quality growth (NYAX, INOD), transition rerating (DUOT), defensive balance (COCO), and catalyst asymmetry (RCAT). Rebalancing is event-driven:

• Add to RCAT only with contract clarity.
• Add to DUOT on recurring KPI improvement.
• Trim INOD/NYAX if growth durability weakens versus expectations.

What Would Make Us Add Weight

A name earns incremental capital when at least two of three conditions are met:

1. Fundamental beat quality improves (not just beats the low bar).
2. Forward commentary upgrades persistence of growth.
3. Liquidity/coverage broadens without valuation fully catching up.

This avoids chasing one-quarter spikes that often reverse in small caps.

Risk Management and Failure Modes

Primary risks include financing shocks, customer concentration surprises, governance slippage in low-float names, and guidance volatility. In this segment, drawdowns are normal; thesis breaks are not. We reduce exposure when growth quality deteriorates structurally, not when price action is noisy.

Key failure modes by name:

• INOD: AI budget normalization faster than expected.
• NYAX: margin compression despite recurring growth.
• RCAT: delayed or lost catalyst.
• DUOT: transition stalls without clear recurring traction.
• COCO: input cost pressure or channel inefficiency.

Final Take

Pre-discovery small-cap investing is about buying before consensus arrives, not fighting it after the rerating. This April 2026 basket offers five different ways to express that thesis with controlled diversification across quality, catalyst intensity, and balance-sheet resilience. The edge is not finding unknown tickers; the edge is distinguishing temporary obscurity from permanent irrelevance.

INOD and NYAX provide the highest-confidence growth core, DUOT is a classic undercovered transition story, RCAT supplies defined event asymmetry, and COCO stabilizes the risk budget. Managed together, the set is designed for asymmetric upside with survivable downside.